This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.
Be willing and able to provide written informed consent/assent.
Must be ≥ 18 years of age on day of signing informed consent.
Be Black / African American per self-report.
Have an ECOG performance status of 0- 2.
Does not plan or is ineligible to receive pembrolizumab with or without chemotherapy per institutional standard/treating provider.
History of allogenic tissue/solid organ transplant.
Received prior treatment chemotherapy and/or immune checkpoint inhibitor therapy in the advanced/metastatic setting for lung cancer.
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy at doses
H. Lee Moffitt Cancer Center and Research Institute
Lead sponsor
Merck Sharp & Dohme LLC
Collaborator
Foundation Medicine
Collaborator
Go-2 Lung
Collaborator